Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab, Short-Course Chemotherapy, and Zevalin in Follicular Lymphoma
NCT00193440Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Apr 2002
- Primary completion
- Apr 2004
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in follicular lymphoma (FL), sponsored by SCRI Development Innovations. Started Apr 2002; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00193440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193440.